End-of-life anticancer treatment – a nationwide registry-based study of trends in the use of chemo-, endocrine, immune-, and targeted therapies

Abstract

We found a stable overall rate at 16% of patients receiving anticancer treatment within one month prior to death in this nationwide sample of cancer deaths. Further research is needed to assess whether this level of end-of-life treatment is justified or reflects inappropriate use.